Drug HighlightTecadenoson: A Novel, Selective A1 Adenosine Receptor AgonistPeterman, Carla PharmD*; Sanoski, Cynthia A. PharmD†Author Information From the *Department of Pharmacy Services, University of Maryland Medical Center, Baltimore, Maryland; and the †Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania. Reprints: Cynthia A. Sanoski, PharmD, University of the Sciences in Philadelphia, Philadelphia College of Pharmacy, Department of Pharmacy Practice and Pharmacy Administration, 600 S. 43rd St., Philadelphia, PA 19104. E-mail: email@example.com. Cardiology in Review: November-December 2005 - Volume 13 - Issue 6 - p 315-321 doi: 10.1097/01.crd.0000181621.84565.9d Buy Metrics Abstract Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. By selectively targeting the A1 receptor, tecadenoson may be associated with fewer adverse effects such as flushing, dyspnea, chest discomfort, and hypotension than adenosine, which is a nonselective agonist of all 4 adenosine receptors. Based on the results of phase I and phase II clinical trials, tecadenoson appears to be an effective agent for producing rapid and sustained conversion of PSVT to sinus rhythm. Additionally, the adverse effects that are typically attributed to adenosine's nonselective stimulation of the A2A, A2B, and A3 receptors appear to occur less frequently with the use of tecadenoson. Tecadenoson also appears to be associated with a lower incidence of atrial fibrillation following conversion of PSVT compared with the rates that have been associated with adenosine in the literature. A randomized, prospective trial will need to be conducted in the future to appropriately compare the safety and efficacy of tecadenoson and adenosine. © 2005 Lippincott Williams & Wilkins, Inc.